Literature DB >> 10682675

IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.

I Kryczek1, M Gryboś, L Karabon, A Klimczak, A Lange.   

Abstract

The presence of interleukin (IL)-6 in peritoneal carcinomatous fluid (PCF) and its effect on immune cells composition in PCF in patients with advanced ovarian carcinoma was studied. In 21 out of 30 ovarian carcinoma patients, PCF IL-6 levels were found to exceed those seen in PCFs of patients with gastrointestinal cancer. IL-6 activity was higher in serous/mucinous than in endometrioid and undifferentiated ovarian carcinoma PCF (P = 0.05). Ovarian carcinoma PCF IL-6 activities were correlated with serum C-reactive protein levels (r = 0.65, P = 0.0000, n = 25). Ovarian carcinoma PCF leucocyte profile differed from that in blood with respect to: (i) lower percentage of NK and CD8+ and (ii) higher percentage of B and CD45RO+, CD14+ and HLA-DR+ cells. The proportions of CD45RO+ in blood were correlated with IL-6 levels in PCF. Corresponding to PCF ovarian carcinoma tumours were stained for the presence of Ki-67 antigen and p53. The highest proportions of Ki-67+ cells and cells showing accumulation of p53 were seen in undifferentiated tumours. A low grade of p53 staining was seen in tumours associated with high IL-6 levels in PCF. It was evident that IL-6 production (i) depended on the histiotype of the tumour, (ii) influenced the local immune system in favour of accumulation of B, and T memory cells, and (iii) was higher in patients lacking p53 accumulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682675      PMCID: PMC2363316          DOI: 10.1054/bjoc.1999.0973

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  Dose intensity in advanced ovarian cancer: have we answered the question?

Authors:  D Fennelly
Journal:  Clin Cancer Res       Date:  1995-06       Impact factor: 12.531

2.  WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability.

Authors:  M K Eskandari; D T Nguyen; S L Kunkel; D G Remick
Journal:  Immunol Invest       Date:  1990-02       Impact factor: 3.657

3.  Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.

Authors:  J S Berek; C Chung; K Kaldi; J M Watson; R M Knox; O Martínez-Maza
Journal:  Am J Obstet Gynecol       Date:  1991-04       Impact factor: 8.661

4.  Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.

Authors:  P H Willemse; E G de Vries; N H Mulder; J G Aalders; J Bouma; D T Sleijfer
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

5.  High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.

Authors:  G Gastl; M Plante; C L Finstad; G Y Wong; M G Federici; N H Bander; S C Rubin
Journal:  Br J Haematol       Date:  1993-03       Impact factor: 6.998

6.  Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.

Authors:  R S Freedman; B Tomasovic; S Templin; E N Atkinson; A Kudelka; C L Edwards; C D Platsoucas
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

Review 7.  Cytokines in malignant lymphomas: review and prospective evaluation.

Authors:  S M Hsu; J W Waldron; P L Hsu; A J Hough
Journal:  Hum Pathol       Date:  1993-10       Impact factor: 3.466

8.  Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms.

Authors:  W H Kutteh; C C Kutteh
Journal:  Am J Obstet Gynecol       Date:  1992-12       Impact factor: 8.661

9.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

10.  Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo.

Authors:  F Takatsuki; A Okano; C Suzuki; R Chieda; Y Takahara; T Hirano; T Kishimoto; J Hamuro; Y Akiyama
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

View more
  13 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

Review 2.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

3.  Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.

Authors:  Rodney E Shackelford; Marilyn M Bui; Domenico Coppola; Ardeshir Hakam
Journal:  Int J Clin Exp Pathol       Date:  2010-06-12

Review 4.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

5.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Authors:  Galina Gritsina; Fang Xiao; Shane W O'Brien; Rashid Gabbasov; Marisa A Maglaty; Ren-Huan Xu; Roshan J Thapa; Yan Zhou; Emmanuelle Nicolas; Samuel Litwin; Siddharth Balachandran; Luis J Sigal; Dennis Huszar; Denise C Connolly
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

Review 6.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07

7.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.

Authors:  Hagen Kulbe; Richard Thompson; Julia L Wilson; Stephen Robinson; Thorsten Hagemann; Rewas Fatah; David Gould; Ayse Ayhan; Frances Balkwill
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

8.  Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Authors:  Khalid Abubaker; Rodney B Luwor; Ruth Escalona; Orla McNally; Michael A Quinn; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed
Journal:  Front Oncol       Date:  2014-04-09       Impact factor: 6.244

Review 9.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

10.  Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; Ai-Qun Wei; Gregory Robertson; David L Morris
Journal:  J Ovarian Res       Date:  2015-08-19       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.